Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients

Endocrine

Volumn 48, Issue 2, 2015, Pages 696-704

  Albu, Alice ^a   Radian, Serban ^a,b   Fica, Simona ^a   Barbu, Carmen Gabriela ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

Hyperandrogenemia; Hyperinsulinemia; Insulin resistance; Metabolic syndrome; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; TESTOSTERONE;

ADOLESCENT; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; ROMANIA; ROMANIAN (CITIZEN); TESTOSTERONE BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; COMORBIDITY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADIPOSITY; ADULT; COMORBIDITY; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; PREVALENCE; ROMANIA; YOUNG ADULT;

EID: 84924152677     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0340-9     Document Type: Article

References (42)

1. I.F. Stein, M.L. Leventhal, Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181–191 (1935)
2. P. Scicchitano, I. Dentamaro, R. Carbonara, G. Bulzis, A. Dachille, P. Caputo, R. Riccardi, M. Locorotondo, C. Mandurino, Ciccone MM, Cardiovascular risk in women with PCOS. Int. J. Endocrinol. Metab. 10(4), 611–618 (2012)
3. L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16(4), 347–363 (2010)
4. J. Vrbikova, K. Vondra, D. Cibula, K. Dvoráková, S. Stanická, D. Srámková, G. Sindelka, M. Hill, B. Bendlová, J. Skrha, Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum. Reprod. 20(12), 3328–3332 (2005)
5. E. Carmina, N. Napoli, R.A. Longo, G.B. Rini, R.A. Lobo, Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur. J. Endocrinol. 154(1), 141–145 (2006)
6. C.J. Glueck, S. Dharashivkar, P. Wang, B. Zhu, P.S. Gartside, T. Tracy, L. Sieve, Obesity and extreme obesity, manifest by ages 20–24 years, continuing through 32–41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur. J. Obstet. Gynecol. Reprod. Biol. 122, 206–212 (2005)
7. H.L. Ching, V. Burke, B.G. Stuckey, Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin. Endocrinol. Oxf. 66, 373–379 (2007)
8. J.C. Lo, S.L. Feigenbaum, J. Yang, A.R. Pressman, J.V. Selby, A.S. Go, Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 1357–1363 (2006)
9. N. Schweighofer, E. Lerchbaum, O. Trummer, V. Schwetz, S. Pilz, T.R. Pieber, B. Obermayer-Pietsch, Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome. Gene 504, 133–139 (2012)
10. E. Carmina, R.S. Legro, K. Stamets, J. Lowell, R.A. Lobo, Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod. 18(11), 2289–2293 (2003)
11. S.F. Witchel, S.E. Recabarren, F. Gonzalez, E. Diamanti-Kandarakis, K.I. Cheang, A.J. Duleba, R.S. Legro, R. Homburg, R. Pasquali, R. Lobo, C.C. Zouboulis, F. Kelestimur, F. Fruzzetti, W. Futterweit, R.J. Norman, D.H. Abbott, Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine 42(3), 526–534 (2012). doi:10.1007/s12020-012-9701-4
12. D.A. Ehrmann, D.R. Liljenquist, K. Kasza, R. Azziz, R.S. Legro, M.N. Ghazzi, PCOS/Troglitazone Study Group, Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 48–53 (2006)
13. A. Dokras, M. Bochner, E. Hollinrake, S. Markham, B. Vanvoorhis, D.H. Jagasia, Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol. 106, 131–137 (2005)
14. A.M. Corbould, M.J. Bawden, T.C. Lavranos, R.J. Rodgers, S.J. Judd, The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. Int. J. Obes. Relat. Metab. Disord. 26(2), 165–175 (2002)
15. J.C. Lovejoy, G.A. Bray, M.O. Bourgeois, R. Macchiavelli, J.C. Rood, C. Greeson, C. Partington, Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women—a clinical research center study. J. Clin. Endocrinol. Metab. 81(6), 2198–2203 (1996)
16. A. Gambineri, C. Pelusi, S. Genghini, A.M. Morselli-Labate, M. Cacciari, U. Pagotto, R. Pasquali, Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. 60(2), 241–249 (2004)
17. M. Allemand, Y. Asmann, K. Klaus, K. Nair, An model for PCOS related insulin resistance: the effects of testosterone on phosphorylation of intracellular insulin signaling proteins in rat skeletal muscle primary culture. Fertil. Steril. 84(Suppl 1), S30–S31 (2005)
18. A. Corbould, Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J. Endocrinol. 192(3), 585–594 (2007)
19. Rotterdam ESHRE/ASRM-Sponsored Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004)
20. H.F. Escobar-Morreale, E. Carmina, D. Dewailly, A. Gambineri, F. Kelestimur, P. Moghetti, M. Pugeat, J. Qiao, C.N. Wijeyaratne, S.F. Witchel, R.J. Norman, Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 18(2), 146–170 (2012)
21. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Asoc. 285(19), 2486–2497 (2001)
22. D. Panidis, D. Macut, K. Tziomalos, E. Papadakis, K. Mikhailidis, E.A. Kandaraki, E.A. Tsourdi, T. Tantanasis, G. Mavromatidis, I. Katsikis, Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 78(4), 586–592 (2013)
23. J.J. Espinós-Gómez, J. Rodriguez-Espinosa, J. Ordóñez-Llanos, J. Calaf-Alsina, Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset. Gynecol. Endocrinol. 28(4), 264–268 (2011)
24. T. Apridonidze, P.A. Essah, M.J. Iuorno, J.E. Nestler, Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929–1935 (2005)
25. A.J. Cussons, G.F. Watts, V. Burke, J.E. Shaw, P.Z. Zimmet, B.G. Stuckey, Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum. Reprod. 23, 2352–2358 (2008)
26. D. Berker, S. Koparal, S. Işik, L. Paşaoğlu, Y. Aydin, K. Erol, T. Delibaşi, S. Güler, Compatibility of different methods for the measurement of visceral fat in different body mass index strata. Diagn Interv Radiol. 16(2), 99–105 (2010)
27. T.M. Barber, S.J. Golding, C. Alvey, J.A. Wass, F. Karpe, S. Franks, M.I. McCarthy, Global Adiposity Rather Than Abnormal Regional Fat Distribution Characterizes Women with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 93, 999–1004 (2008)
28. H.F. Escobar-Morreale, S. Samino, M. Insenser, M. Vinaixa, M. Luque-Ramírez, M.A. Lasunción, X. Correig, Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin. Chem. 58(6), 999–1009 (2009)
29. D. Dewailly, P. Pigny, B. Soudan, S. Catteau-Jonard, C. Decanter, E. Poncelet, A. Duhamel, Reconciling the Definitions of Polycystic Ovary Syndrome: The Ovarian Follicle Number and Serum Anti-Mullerian Hormone Concentrations Aggregate with the Markers of Hyperandrogenism. J. Clin. Endocrinol. Metab. 95, 4399–4405 (2010)
30. Alebić, M.S., Bulum, T., Stojanović, N., Duvnjak, L.: Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine. Feb 13. (2014) [Epub ahead of print]
31. J.H. Fox, T. Licholai, G. Green, A. Dunaif, Differential effects of oral glucose-mediated versus intravenous hyperinsulinemia on circulating androgen levels in women. Fertil. Steril. 60(6), 994–1000 (1993)
32. E.P. Wickham, K.G. Ewens, R.S. Legro, A. Dunaif, J.E. Nestler, J.F. Strauss 3rd, Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 96(4), 719–727 (2011)
33. D. Glintborg, H. Mumm, P. Ravn, M. Andersen, Age associated differences in prevalence of individual Rotterdam criteria and metabolic risk factors during reproductive age in 446 caucasian women with polycystic ovary syndrome. Horm. Metab. Res. 44(9), 694–698 (2012)
34. M.O. Goodarzi, N.A. Shah, H.J. Antoine, M. Pall, X. Guo, R. Azziz, Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J. Clin. Endocrinol. Metab. 91(10), 4085–4091 (2006)
35. W.Y. Chang, E.S. Knochenhauer, A.A. Bartolucci, R. Azziz, Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil. Steril. 83(6), 1717–1723 (2005)
36. J.S. Brand, I. van der Tweel, D.E. Grobbee, M.H. Emmelot-Vonk, Y.T. van der Schouw, Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int. J. Epidemiol. 40, 189–207 (2011)
37. M.E. Zanolin, F. Tosi, G. Zoppini, R. Castello, G. Spiazzi, R. Dorizzi, M. Muggeo, P. Moghetti, Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women. Diabetes Care 29, 372–378 (2006)
38. P.M. Nilsson, G. Engström, B. Hedblad, The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects—a population-based study comparing three different definitions. Diabet. Med. 24, 464–472 (2007)
39. C. Lorenzo, M. Okoloise, K. Williams, M.P. Stern, S.M. Haffner, The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26, 3153–3159 (2003)
40. A.J. Hanley, A.J. Karter, K. Williams, A. Festa, R.B. D’Agostino Jr, L.E. Wagenknecht, S.M. Haffner, Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 112, 3713–3721 (2005)
41. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009)
42. E. Lerchbaum, V. Schwetz, A. Giuliani, T.R. Pieber, B. Obermayer-Pietsch, Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil. Steril. 98, 1318–1325 (2012)